/
BVS
$9.78+$0.00 (+0.00%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$662.6M
68M shares
52-week range
$5.81 – $11.25
73% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.50%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-7.43
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $319.2M | $340.1M | $321.2M | $430.9M | $512.1M | $512.3M | $573.3M | $568.1M |
| Cost of revenue | $84.2M | $90.9M | $87.6M | $128.2M | $181.0M | $184.2M | $185.1M | $185.7M |
| Gross profit | $235.0M | $249.2M | $233.5M | $302.7M | $331.1M | $328.2M | $388.2M | $382.4M |
| Gross margin | 73.6% | 73.3% | 72.7% | 70.3% | 64.6% | 64.1% | 67.7% | 67.3% |
| R&D | $8.1M | $11.1M | $11.2M | $19.0M | $23.9M | $13.4M | $13.6M | $12.1M |
| Operating income | $25.5M | $31.2M | $21.2M | $12.1M | −$167.2M | −$81.7M | −$12.0M | $58.5M |
| EBITDA | $54.5M | $61.6M | $54.3M | $45.5M | −$121.6M | −$23.1M | $39.2M | $99.2M |
| Net income | −$12.2M | $6.9M | $16.4M | $19.4M | −$158.7M | −$156.2M | −$33.5M | $22.7M |
| Net margin | -3.8% | 2.0% | 5.1% | 4.5% | -31.0% | -30.5% | -5.9% | 4.0% |
| EPS (diluted) | -0.22 | 0.12 | 0.44 | -0.15 | -2.59 | -2.49 | -0.52 | 0.33 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $605M | $0.78 | $0.77–$0.79 | 4 |
| 2027 | $645M | $0.91 | $0.89–$0.92 | 4 |
| 2028 | $685M | $1.07 | $0.76–$1.40 | 3 |
| 2029 | $737M | $1.07 | $1.06–$1.08 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Bioventus Inc. Class A Common Stock
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
www.bioventus.com- Employees
- 940
- IPO / List date
- Feb 11, 2021
- HQ
- DURHAM, NC
Held by traders on TradeandTell
No one on the platform currently holds BVS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 489,460 | $4.5M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded BVS yet.
